

Participant ID	MCN
US3482155	N/A
<b>Preferred Term(s):</b>	Swelling face
<b>Treatment Assignment:</b>	mRNA-1273
<b>Relationship</b>	Not Related
<b>Baseline SARS-CoV-2</b>	Negative

A 38 year old black female, not Hispanic participant, experienced a non-serious event of swelling face. Her medical history included sleep disorder, anxiety, seasonal allergies, bilateral tubal ligation, helicobacter infection, and GERD. On 27 August 2020, the participant received the first dose of study medication. The participant received the second dose of study drug on 25 September 2020.

On 31 October 2020, 36 days after administration of the second dose, the participant experienced a non-serious event of swelling face (verbatim: left sided swelling of the face) mild in severity and non-serious. The participant was treated with ibuprofen on 02 Nov 2020. The event resolved on 08 November 2020. The events were assessed as not related by the study investigator.

The participant also reported the non-serious adverse events of upper respiratory tract infection and upper respiratory tract illness from 16 to 31 October and 1 to 15 November, respectively. Both were assessed as mild in severity, non-serious and not related to study product.

Participant ID	MCN
US3672261	N/A
<b>Preferred Term(s):</b>	Swelling face
<b>Treatment Assignment:</b>	mRNA-1273
<b>Relationship</b>	Not Related
<b>Baseline SARS-CoV-2</b>	Positive

A 27 year old white female, Not Hispanic participant, experienced a non-serious event of swelling face. Her medical history included lactose intolerance. On 21 August 2020, the participant received the first dose of study medication. The participant received the second dose of study drug on 22 September 2020.

On 08 September 2020, 18 days after administration of the first dose, the participant experienced a non-serious event of swelling face (verbatim: right lower face swelling). The event was assessed as moderate in severity and non-serious. The participant was not treated for this event. The event resolved on 16 September 2020 and was assessed as not related by the study investigator. The patient went on to receive the second dose of study medication without incident.

Participant ID	MCN
US3602084	N/A
<b>Preferred Term(s):</b>	Swelling face
<b>Treatment Assignment:</b>	Placebo
<b>Relationship</b>	Not Related
<b>Baseline SARS-CoV-2</b>	Negative

A 42 year old male (race not reported), Not Hispanic participant, experienced a non-serious event of swelling face. His medical history included diabetes mellitus type 2, obesity, pituitary tumor, fatty liver disease and seasonal allergies n. On 22 September 2020, the participant received the first dose of study medication. The participant received the second dose of study drug on 21 October 2020.

On 08 October 2020, 16 days after administration of the first dose, the participant experienced a non-serious event of swelling face (verbatim: swelling on left side of cheek) assessed as mild in severity and non-serious. On the same day he began experiencing swelling, redness, and soreness to the inside of his left cheek which made the soreness uncomfortable and difficult to chew. The participant did not seek medical attention and did not receive any treatment. The events resolved on 17 October 2020 and was assessed as not related by the study investigator. The patient went on to receive the second dose of study medication without incident.